Sign In
Buy EXEL
$51.60
+3.06 (+6.30%)
At Close: Jun 03, 2026
Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories
01:57pm, Tuesday, 15'th Oct 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-002
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
10:00am, Tuesday, 15'th Oct 2024
EXEL is set to evaluate investigational zanzalintinib in combination with Merck;s Keytruda (pembrolizumab) and Welireg in head and neck cancer and renal cell carcinoma, respectively.
ALAMEDA, Calif. & RAHWAY, N.J.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have ente
Exelixis Gains 20.7% in Three Months: Is This the Right Time to Buy?
11:26am, Monday, 07'th Oct 2024
EXEL stock surges 20.7% on encouraging performance of its lead drug Cabometyx and impressive pipeline progress. We are optimistic about the stock as we believe there is room for growth.
EXEL vs. CSLLY: Which Stock Is the Better Value Option?
12:46pm, Wednesday, 02'nd Oct 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more a
2 Growth Stocks to Buy With Less Than $100
08:45am, Thursday, 26'th Sep 2024
With e-commerce accounting for just 16% of U.S. retail sales, Shopify has plenty of runway ahead. Exelixis is an innovative drugmaker focusing on one of the most competitive areas in the industry.
Here's Why Exelixis (EXEL) is a Strong Momentum Stock
10:56am, Friday, 20'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here's Why Exelixis (EXEL) is a Strong Value Stock
10:47am, Monday, 16'th Sep 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 02'nd Sep 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
EXEL vs. CSLLY: Which Stock Should Value Investors Buy Now?
12:40pm, Thursday, 29'th Aug 2024
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Exelixis (EXEL) or CSL Limited Sponsored ADR (CSLLY). But which of these two stocks is more a
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term
10:41am, Thursday, 29'th Aug 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
5 Top-Ranked Value Stocks With Discounted PEG Ratio to Buy
10:01am, Thursday, 29'th Aug 2024
Five PEG-based stocks that fulfill our screening criteria are Genpact, MPLX, Exelixis, Paramount Global and H&R Block.
Exelixis to Webcast Fireside Chats as Part of Investor Conferences in September
04:05pm, Wednesday, 28'th Aug 2024
ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in September: Morgan St
Why Exelixis (EXEL) Might be Well Poised for a Surge
01:20pm, Monday, 26'th Aug 2024
Exelixis (EXEL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Exelixis Earnings Drive Share Growth
08:09am, Friday, 16'th Aug 2024
Oncology company Exelixis, Inc. (EXEL) reported better-than-expected results, driving big share gains.
